AstraZeneca shares fell 9% in European stock trading after a late-stage clinical trial of its nervous system disease treatment WAINUA failed to meet expectations.
According to Jin10, the decline followed news that the late-stage trial results for WAINUA did not match what had been anticipated.
STOCKS | AstraZeneca Shares Fall 9% After Late-Stage Trial Misses Expectations
2026-07-09 07:13:22
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
